目的 探討燈盞花素注射液聯(lián)合曲克蘆丁治療急性腦梗死患者的臨床療效。方法 選取2019年1月—2020年3月在天津市泰達(dá)醫(yī)院診治的120例急性腦梗死患者為研究對(duì)象，隨機(jī)分為對(duì)照組和治療組，每組各60例。對(duì)照組患者靜脈滴注注射用曲克蘆丁，0.48 g加入5%葡萄糖注射液250 mL，1次/d；治療組患者在對(duì)照組基礎(chǔ)上靜脈滴注燈盞花素注射液，20 mg加入生理鹽水250 mL中，1次/d。兩組患者均治療2周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者神經(jīng)功能缺損評(píng)分、日常生活活動(dòng)能力評(píng)分、缺血半暗帶體積及血栓素A2（TXA2）、前列腺素（PGI2）、TXA2/PGI2、過氧化氫酶（CAT）、谷胱甘肽過氧化物酶（GSH-Px）、過氧化脂質(zhì)（LPO）、S100鈣結(jié)合蛋白β（S100β）和膠質(zhì)纖維酸性蛋白（GFAP）水平。結(jié)果 治療后，對(duì)照組臨床有效率為85.00%，顯著低于治療組的96.67%（P<0.05）。治療后，兩組患者NIHSS評(píng)分顯著降低，F(xiàn)IM評(píng)分較治療前均顯著提高（P<0.05），且治療組患者NIHSS評(píng)分、FIM評(píng)分改善更明顯，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者缺血半暗帶體積較治療前顯著降低（P<0.05），且治療組缺血半暗帶體積降低的更明顯（P<0.05）。治療后，兩組患者TXA2、TXA2/PGI2、LPO、S100β、GFAP水平較治療前均顯著降低，PGI2、CAT、GSH-Px水平較治療前均顯著升高（P<0.05），且治療組患者上述指標(biāo)改善更明顯，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 燈盞花素注射液聯(lián)合曲克蘆丁可顯著改善急性腦梗死患者的神經(jīng)功能，有效抑制氧化應(yīng)激反應(yīng)，臨床療效佳，且安全性高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Dengzhanhuasu Injection combined with troxerutin in treatment of acute cerebral infarction. Methods Patients (120 cases) with acute cerebral infarction in Tianjin TEDA Hospital from January 2019 to March 2020 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Troxerutin for injection, 0.48 g added into 5% glucose injection 250 mL, once daily. Patients in the treatment group were iv administered with Dengzhanhuasu Injection on the basis of the control group, 20 mg added into normal saline 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the neurological deficit score, activity of daily living score, ischemic penumbra volume, and the levels of TXA2, TXA2/PGI2, PGI2, CAT, GSH-Px, LPO, S100β and GFAP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 85.00%, which was significantly lower than 96.67% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the NIHSS score in two groups was significantly decreased, and the FIM score was significantly increased compared with before treatment (P<0.05), and the NIHSS score and FIM score in the treatment group were improved more obviously, the difference was statistically significant (P<0.05). After treatment, the volume of ischemic penumbra in two groups was significantly decreased compared with that before treatment (P<0.05), and the volume of ischemic penumbra in the treatment group was more significantly decreased (P<0.05). After treatment, the levels of TXA2, TXA2/PGI2, LPO, S100β and GFAP in two groups were significantly decreased compared with before treatment, while the levels of PGI2, CAT and GSH-Px were significantly increased compared with before treatment (P<0.05), and the improvement of above indexes in the treatment group was more obvious. The difference between the two groups was statistically significant (P<0.05). Conclusion Dengzhanhuasu Injection combined with troxerutin can significantly improve the neurological function in treatment of acute cerebral infarction, effectively inhibit oxidative stress reaction, with better clinical efficacy and higher safety, which has a certain clinical application value.

R971